A Study of a 35 mg Delayed Release Formulation of Risedronate for Osteoporosis

PHASE3CompletedINTERVENTIONAL
Enrollment

923

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

April 30, 2010

Study Completion Date

April 30, 2010

Conditions
Postmenopausal Osteoporosis
Interventions
DRUG

risedronate

5 mg Immediate-release Risedronate Administered At Least 30 Minutes Before Breakfast Daily

DRUG

risedronate

35 mg Delayed-release Risedronate Administered Immediately Following Breakfast Weekly

DRUG

risedronate

35 mg Delayed-release Risedronate Administered At Least 30 Minutes Before Breakfast Weekly

Trial Locations (45)

Unknown

Research Site, Birmingham

Research Site, Oakland

Research Site, San Diego

Research Facility, Walnut Creek

Research Site, Walnut Creek

Research Site, Lakewood

Research Site, Leesburg

Research Site, Melbourne

Research Site, South Miami

Research Site, Gainesville

Research Site, Champaign

Research Site, Chicago

Research Site, Bethesda

Research Site, Brockton

Research Site, Omaha

Research Site, Las Vegas

Research Site, Greenville

Research Site, Portland

Research Site, Seattle

Research Site, Madison

Research Site, Buenos Aires

Research Facility, Diepenbeek

Research Site, Ghent

Research Site, Leuven

Research Site, Hamilton

Research Site, Kitchener

Research Site, Newmarket

Research Site, Montreal

Research Site, Québec

Research Site, Saint-Eustache

Research Site, Saskatoon

Research Site, Pärnu

Research Site, Tallinn

Research Site, Tartu

Research Site, Amiens

Research Site, Lyon

Research Site, Orléans

Research Site, Vandœuvre-lès-Nancy

Research Site, Balatonfüred

Research Site, Debrecen

Research Site, Eger

Research Site, Győr

Research Site, Koranyi Sandor

Research Site, Bialystok

Research Site, Warsaw

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Warner Chilcott

INDUSTRY

NCT00541658 - A Study of a 35 mg Delayed Release Formulation of Risedronate for Osteoporosis | Biotech Hunter | Biotech Hunter